| 271 | 23 | 2 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察补肾通络方对糖尿病肾病患者炎症因子TNF-α、MCP-1的作用。方法:将符合诊断标准的糖尿病肾病(DN)患者随机分为治疗组和对照组,治疗组在西医常规治疗的基础上加用中药补肾通络方进行治疗,对照组单纯用西药治疗,分别于治疗前、后抽血检测C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)、单核细胞趋化蛋白(MCP-1)、糖化血红蛋白、空腹血糖、餐后2 h血糖等指标,收集尿液检测尿微量白蛋白。结果:治疗组患者的血糖、糖化血红蛋白较对照组有所下降,但无统计学意义。治疗组患者的CRP、TNF-α、MCP-1等指标均显著下降(P<0.01)。结论:补肾通络方能降低糖尿病肾病患者血中CRP、TNF-α、MCP-1的含量,减轻糖尿病肾病患者的炎症反应。
Abstract：[1]中华中医药学会.糖尿病中医防治指南[Z].北京:中国中医药出版社,2007:14.
[2]Niewczas MA,Ficociello LH,Johnson AC,et al.Serum con-centrations of markers of TNF-alpha and Fas-mediated pathways and renal function in nonproteinuric patients with type1diabetes[J].Clin J Am Soc Nephrol,2009,4(1):62-70.
[3]Ilona Idasiak-Piechocka,Andrzej Oko,Elzbieta Pawliczak,et al.Urinary excretion of soluble tumour necrosi sfactor re-ceptor1as a marker of increased risk ofprogressive kidney function deterioration in patients with primary chronicglo-merulonephritis[J].Nephrol Dial Transplant,2010,25(6):3948-3956.
[4]Ng DP,Fukushima M,Tai BC,et al.Reduced GFR and al-buminuria in Chinese type2diabetes mellitus patients are both independently associated with activation of the TNF-alpha system[J].Diabetologia,2008,51(12):2318-2324.
[5]Navarro-Gonzalez JF,Jarque A,Muros M,et al.Tumor nec-rosis factor-alpha as a therapeutic target for diabetic ne-phropathy[J].Cytokine Growth Factor Rev,2009,20(2):165-173.
[6]Thomas A Wynn,Luke Barron.Macrophages:Master Regu-lators of Inflammation and Fibrosis[J].Semin Liver Dis,2010,30(3):245-257.
[7]Bo Jiao,Yunshan,Yanna,et al.Valsartan attenuated oxida-tive stress,decreased MCP-1and TGF-βexpression in glo-merular mesangial and epithelial cells induced by high-glu-cose levels[J].BioScience Trends,2011,5(4):173-181.
[8]闵存云.牡丹皮对糖尿病患者CRP、TNF、IL-6的影响[J].中药材,2009,32(9):1490-1492.
[9]闵存云,王昌俊,詹锋.补肾通络方防治糖尿病肾病的临床观察[J].中药材,2010,33(12):1976-1979.
[10]闵存云,付婷婷,杜玉,等.补肾通络方对糖尿病肾病患者CTGF、MMP的影响[J].中药材,2012,35(3):507-509.
基本信息:
DOI：10.13863/j.issn1001-4454.2013.02.004
中图分类号:R277.5
引用信息:
[1]闵存云,陈奕伸,付婷婷等.补肾通络方对糖尿病肾病患者炎症因子的影响[J].中药材,2013,36(02):334-337.DOI:10.13863/j.issn1001-4454.2013.02.004.
基金信息:
广东省自然科学基金项目(S2012010010783);; 广东省中医药管理局项目(20111108)